Author: Fiona Craig

Eurasia Mining PLC (LSE:EUA) has received a two-year extension on its NKT mine license, a Tier-1 scale project located adjacent to the Monchetundra mine. This extension allows the company to transition the mine smoothly to a production permit, supporting Eurasia’s strategy to enhance shareholder value and advance its Russia exit plan. With existing infrastructure and low capital expenditure requirements, the NKT mine provides a competitive advantage and potential for a significant liquidity event benefiting both the company and its stakeholders.

The company’s outlook is influenced by weak financial performance, including negative profitability and irregular cash flows. Nevertheless, strategic corporate initiatives—such as operational upgrades and its dual listing—offer positive growth prospects. Technical indicators suggest moderate strength, although valuation concerns persist due to ongoing losses.

About Eurasia Mining PLC

Eurasia Mining PLC specializes in the extraction of iridium, osmium, palladium, platinum, rhodium, ruthenium, and gold. The company focuses on strategic mining operations in the Arctic region, leveraging its Monchetundra and NKT assets to maintain a competitive edge with low capital expenditure.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

ECR Minerals (LSE:ECR) has completed alluvial drilling at its Blue Mountain Project in Queensland, confirming visible gold at multiple prospects and, for the first time, identifying coarse gold at Upper Kariboe Creek. The company plans to conduct trial wash testing to evaluate recovery rates and ore grades. Meanwhile, drilling is scheduled to begin at the Lolworth Project, focusing on the Uncle Terry prospect, which has previously exhibited high-grade gold and significant mineralization. These activities underscore ECR’s strategic efforts to advance its gold exploration portfolio, potentially boosting production potential and strengthening its market position.

About ECR Minerals

ECR Minerals is an exploration and development company specializing in gold projects across Australia. Its portfolio includes full ownership of the Bailieston and Creswick gold projects in Victoria, as well as exploration permits in Queensland, including the Lolworth Range. The company is actively working to explore and develop these assets to enhance their production prospects.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Aminex plc (LSE:AEX) has reported key progress on its Ntorya gas field project in Tanzania. The Tanzania Petroleum Development Corporation (TPDC) has begun procurement for the construction of a pipeline connecting the field to the Madimba gas processing plant, with groundwork scheduled to start in January 2026 and completion anticipated by July 2026. In addition, the Petroleum Upstream Regulatory Authority (PURA) has approved the tender strategy for drilling and workover operations, representing significant milestones for the project. These developments highlight the Tanzanian government’s commitment to strengthening energy supply and supporting industrial growth, positioning Aminex to benefit from increased gas production without additional capital outlay.

About Aminex plc

Aminex plc is an oil and gas exploration and development company focused on Tanzania. The firm holds a 25% non-operated interest in the Ntorya gas field, which is intended to supply gas to the domestic market, contributing to the country’s energy transition and broader economic growth.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Journeo plc (LSE:JNEO) has received approximately £1 million in purchase orders from a major local authority in Southern England to enhance passenger information display infrastructure and software, supporting the authority’s Bus Service Improvement Plan. The orders include high-definition displays, audio solutions for visually impaired passengers, and interactive totem technology. In addition, Journeo has won contracts for its integrated airport transfer and real-time information systems at Leeds Bradford and Dublin Airports, bringing its presence to eight major airports across the UK and Ireland. This expansion highlights Journeo’s ability to improve public transport and airport operations, supporting over 210 million passenger journeys annually.

The company’s strong financial performance, including solid revenue and profit growth, effective cash flow management, and low leverage, underpins its positive stock rating. Technical indicators show some short-term bearish momentum, while valuation metrics suggest the stock remains attractively priced. The lack of recent earnings calls or corporate events does not materially affect the outlook.

About Journeo plc

Journeo plc is a leading provider of Intelligent Transport Systems, delivering solutions for urban areas, airports, and public transport networks. The company works closely with local authorities, Network Rail, and major multinational transport operators. Its five operating companies focus on fleet management systems, passenger systems, rail information displays, and technical services across Scandinavia. Significant R&D investment enables Journeo to provide innovative, scalable, and integrated solutions for modern public transport needs.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Aptamer Group plc (LSE:APTA) has launched a new biomarker discovery service using its proprietary Optimer® technology to accelerate the identification of disease-specific biomarkers. Offered on a fee-for-service basis, the service is designed to deliver rapid, validated biomarkers suitable for drug development, supporting revenue growth and diversifying the company’s income streams. The service addresses increasing demand from pharmaceutical, biotech, and diagnostic companies driven by the expansion of precision medicine and has already demonstrated potential through successful internal applications.

While the company faces significant financial challenges and weak technical indicators, recent corporate developments and strategic partnerships provide optimism for future growth. High levels of debt and ongoing unprofitability remain key considerations for investors.

About Aptamer Group Plc

Aptamer Group plc is a leading life sciences company specializing in next-generation synthetic binders. It focuses on innovative solutions for the biomarker discovery sector, a market currently valued at $62.4 billion worldwide.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Savannah Energy (LSE:SAVE) reported a 4% increase in total revenues, reaching $147.3 million for the first seven months of 2025, alongside a 37% growth in cash collections. The company has secured a drilling contract for the Uquo Field in Nigeria, with substantial gas production anticipated by early 2026. Other strategic initiatives include the expansion of the Stubb Creek asset and ongoing discussions for a joint development agreement in Cameroon. These efforts reflect Savannah’s focus on boosting production capacity and expanding its asset portfolio, potentially strengthening its market position and creating growth opportunities for stakeholders.

About Savannah Energy PLC

Savannah Energy PLC is a British independent energy company engaged in oil and gas production. The firm operates primarily in West and Central Africa, with active projects in Nigeria, Niger, Chad, and Cameroon, aiming to deliver sustainable, high-impact energy developments.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Shield Therapeutics (LSE:STX) has reported encouraging results from the ORION-HF study, which showed meaningful improvements in haemoglobin levels, exercise capacity, and quality of life for patients with heart failure and iron deficiency anemia treated with FeRACCRU® (ferric maltol). Published in the European Journal of Heart Failure, the findings suggest that ferric maltol could serve as an effective oral alternative to intravenous iron therapies, addressing a notable unmet need in heart failure management. These results align with previous research and may strengthen Shield’s market positioning and investor confidence in the therapeutic potential of ACCRUFeR®/FeRACCRU®.

While the company demonstrates strong technical momentum and market interest, financial challenges—such as ongoing losses and negative cash flow—remain significant. Valuation metrics, including a negative P/E ratio and lack of dividend yield, also limit the stock’s appeal despite promising clinical developments.

About Shield Therapeutics

Shield Therapeutics plc is a specialty pharmaceutical company at the commercial stage, focused on treating iron deficiency with or without anemia. Its lead product, ACCRUFeR®/FeRACCRU® (ferric maltol), offers a novel oral absorption mechanism compared to traditional iron therapies. Shield has launched ACCRUFeR® in the U.S. through a partnership with Viatris and has licensed rights to multiple pharmaceutical companies for commercialization across Europe, China, Japan, and other regions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Foresight Environmental Infrastructure Limited (LSE:FGEN) has sold its 50% stake in the Lunanhead battery energy storage project in Scotland, reflecting its strategic approach to capital allocation and optimizing shareholder returns. At the same time, the company’s Sandridge battery energy storage system in Wiltshire has been energized and is approaching commercial operation, strengthening FGEN’s operational portfolio and supporting renewable energy integration and grid stability.

About Foresight Environmental Infrastructure Limited

Foresight Environmental Infrastructure Limited (FGEN) invests in environmental infrastructure assets across the UK and Europe, focusing on renewable energy generation, energy infrastructure, and sustainable resource management. The company aims to deliver stable returns and predictable income while promoting decarbonization and long-term sustainability. FGEN targets projects with secure revenues and stable cash flows, providing investors with sustainable dividends and potential for capital growth.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Defence Holdings PLC (LSE:ALRT) has named Richard Bassett as Vice President of Defence Programmes, a key leadership move designed to enhance the company’s operational credibility and strengthen senior-level military relationships. With extensive experience in the defence sector, Bassett is expected to accelerate the company’s efforts to secure front-line defence contracts and ensure its technology initiatives align with the operational priorities of the UK Ministry of Defence and NATO partners. This addition to the leadership team underscores Defence Holdings’ commitment to expanding its competitive edge in AI and defence-related contracts.

About Defence Holdings PLC

Defence Holdings PLC is the UK’s first listed software-led defence company, dedicated to delivering sovereign digital capabilities in areas of national security, resilience, and defence readiness.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Primary Health Properties PLC (LSE:PHP) has completed the closing of its revised offer to acquire Assura PLC after securing valid acceptances representing about 92.02% of Assura’s issued ordinary share capital. With this threshold surpassed, PHP will move forward with a compulsory acquisition of the remaining shares. Once finalized, Assura will be delisted from both the London Stock Exchange and the JSE, and re-registered as a private limited company. This transition will significantly reduce the liquidity of Assura shares, leaving minority shareholders with limited options for selling or collecting future dividends.

Financially, Primary Health Properties remains on solid footing, backed by strong equity and zero debt, which supports operational resilience. Technical indicators point to continued upward momentum, though its elevated P/E ratio suggests possible overvaluation. The company’s strategic acquisition of Assura strengthens its market position, while management commentary highlights growth opportunities through rising rental income and effective asset management, despite some operational hurdles.

About Primary Health Properties PLC (REIT)

Primary Health Properties PLC is a real estate investment trust specializing in the ownership and management of primary healthcare facilities across the UK and Ireland. Its portfolio is centered on modern, purpose-built medical centers, primarily leased to general practitioners, the National Health Service, and other healthcare providers.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.